News Sentiment

OTLK sentiment intelligence

OUTLOOK THERAPEUTICS INC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.57 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Guidance

88/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+8.3% over one week, +28.7% over four weeks, trend active, and below fair value.

Latest direct headline Positive

$Outlook Therapeutics (OTLK.US)$ looks like a cup and handle on the daily ans weekly chart. this should take off soon.

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Guidance 88/100 classification
One-week reaction 8.3% Price confirming higher
Trend fit Trend active 28.7% over four weeks
Fair value -68.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 9
Stock Titan 5
Moomoo 4
GlobeNewswire 4
simplywall.st 4
StocksToTrade 3
MT Newswires 3

Event Lens

What the news is about

Classified themes
Guidance 45
Earnings 14

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
TechStock² Direct company coverage

Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms

Outlook Therapeutics' stock surged by about 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration, with a PDUFA date set for July 29, 2026. This acceptance provides a clearer regulatory path, but the company sti

Tone
Positive 70/100
Event
Guidance
Published
16 Jun 2026 20:09
Source
TechStock²
Investing.com Direct company coverage

Outlook Therapeutics stock surges on FDA BLA resubmission

Outlook Therapeutics Inc. (NASDAQ:OTLK) shares rose after the FDA accepted its resubmitted Biologics License Application for ONS-5010/LYTENAVA, aimed at treating wet age-related macular degeneration. The FDA has set a target action date of July 29, 2026, for this Class 1 review.

Tone
Positive 94/100
Event
Guidance
Published
16 Jun 2026 14:09
Source
Investing.com
TradingView Direct company coverage

Outlook Therapeutics: FDA accepts resubmitted BLA for ONS-5010 with PDUFA date July 29, 2026

Outlook Therapeutics announced that the FDA has accepted its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for the treatment of wet Age-related Macular Degeneration (AMD). The FDA has designated this resubmission for a Class 1 review, setting a P

Tone
Positive 74/100
Event
Guidance
Published
16 Jun 2026 13:09
Source
TradingView
GlobeNewswire Direct company coverage

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Outlook Therapeutics announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat wet AMD. The resubmission is designated as a Class 1 review, with a Prescription Drug User Fee Act (PDUFA) targe

Tone
Positive 70/100
Event
Guidance
Published
16 Jun 2026 12:09
Source
GlobeNewswire